At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 122 enrolled
Drug / intervention
Insulin Lispro +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Crossover Trial Comparing the Safety and Efficacy of Insulin Lispro With the Safety and Efficacy of Insulin Aspart in Subjects With Type 2 Diabetes on CSII Therapy
In Brief
A Phase 3 clinical trial evaluating Insulin Lispro and Insulin Aspart for Type 2 Diabetes Mellitus. Completed, enrolled 122 participants across 12 sites.
Detailed Summary
This study will provide information on the use of insulin lispro and insulin aspart in insulin pumps in participants with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionFeb 2013
TodayJul 2026
First PostedNov 18, 2011
Enrollment StartDec 1, 2011
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.6 years ago
Interventions
Insulin Lisprodrug
Insulin lispro (100 U/mL) administered by CSII pump
Insulin Aspartdrug
Insulin aspart (100 U/mL) administered by CSII pump